Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.69 |
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA7 | P43166 | 3/20 | 0.69 |
| ▸ | CA9 | Q16790 | 3/20 | 0.69 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.69 |
| ▸ | RELA | Q04206 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3796697 | 0.91 | CA12 (0.82) | CA12CA1CA7CA9CA13 | |
| SCHEMBL941424 | 0.82 | RELA (1.00) | CA12CA1CA7CA9CA13 | |
| SCHEMBL30608638 | 0.82 | RELA (1.00) | CA12CA1CA7CA9CA13 | |
| SCHEMBL940860 | 0.79 | CA12 (0.84) | CA12CA1CA7CA9CA13 | |
| SCHEMBL11218491 | 0.77 | CA12 (0.67) | CA12CA1CA7CA9CA13 | |
| SCHEMBL10079564 | 0.74 | ALDH1A1 (0.67) | CA12CA1CA7CA9CA13 | |
| SCHEMBL38658338 | 0.74 | CA12 (0.84) | CA12CA1CA7CA9CA13 | |
| SCHEMBL941032 | 0.72 | KDM4E (1.00) | CA12CA1CA7CA9CA13 | |
| SCHEMBL29508368 | 0.72 | KDM4E (1.00) | CA12CA1CA7CA9CA13 | |
| SCHEMBL13815272 | 0.72 | CA12 (0.58) | CA12CA1CA7CA9CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1932514-B1 | PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR | EZAKI GLICO CO (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-20140023602-A1 | EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE | EZAKI GLICO CO., LTD. (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20110014141-A1 | TOPICAL AGENT FOR DERMATOLOGICAL USE | DSM IP ASSETS B.V. (NL) | 2011-01-20 | — | — | US | disclosed |
| EP-1932514-A1 | PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR | Ezaki Glico Co., Ltd. (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-1859835-A2 | Topical agent for dermatological use containing 4-hydroxyphenyl-alpha-D-glucopyranoside | PENTAPHARM Ltd. (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-20030198610-A1 | Topical agent for dermatological use | DSM IP ASSETS B.V. (NL) | 2003-10-23 | — | — | US | disclosed |
| EP-1289489-A2 | TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE | PENTAPHARM Ltd. (CH) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001091715-A2 | TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE | PENTAPHARM LTD. (CH) | 2001-12-06 | — | — | WO | disclosed |
| US-6066312-A | SKIN-LIGHTENING AND WHITENING EFFECTS | LION CORPORATION (JP) | 2000-05-23 | — | — | US | disclosed |
| EP-0294808-B1 | AGENT FOR EXTERNAL APPLICATION AND USE THEREOF | LION CORPORATION (JP) | 1992-04-22 | — | — | EP | disclosed |
| EP-0294808-A1 | Agent for external application and use thereof | LION CORPORATION (JP) | 1988-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014141-A1 | TOPICAL AGENT FOR DERMATOLOGICAL USE | GALE, ALPP, UGGT1 | CA12 1408/4885CA1 3805/4885CA7 1150/4885 |
| US-20140023602-A1 | EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE | SI, CUTA, CD44 | CA12 173/4885CA1 356/4885CA7 252/4885 |
| US-20030198610-A1 | Topical agent for dermatological use | GALE, UGGT1, UGDH | CA12 1338/4885CA1 3907/4885CA7 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.